首页> 美国卫生研究院文献>Molecular Medicine Reports >SCRG1 suppresses LPS-induced CCL22 production through ERK1/2 activation in mouse macrophage Raw264.7 cells
【2h】

SCRG1 suppresses LPS-induced CCL22 production through ERK1/2 activation in mouse macrophage Raw264.7 cells

机译:SCRG1通过小鼠巨噬细胞Raw264.7细胞中的ERK1 / 2激活抑制LPS诱导的CCL22产生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, we identified the scrapie responsive gene 1 (SCRG1) secreted from mesenchymal stem cells (MSCs) and its receptor bone marrow stromal cell antigen 1 (BST1) as positive regulators of stem cell qualities such as self-renewal, migration abilities, and osteogenic differentiation potential. Here, we examined the effect of the paracrine activity of SCRG1 in macrophages. The mouse macrophage-like cell line Raw264.7 expressed BST1/β1 or BST1/β2 integrin as possible SCRG1 receptors. Unexpectedly, recombinant SCRG1 did not enhance cell proliferation, migration, or adhesion in these macrophages. However, further examination of the effect of SCRG1 in Raw264.7 cells did reveal a potent anti-inflammatory effect whereby SCRG1 suppressed LPS-induced CCL22 production. SCRG1 also induced the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in these cells and, moreover, a mitogen-activated protein kinase (MAPK)/ERK kinase inhibitor U0126 significantly suppressed the effect of SCRG1 on LPS-induced chemokine CCL22 production. Taken together, these data indicate that SCRG1 signals through the MAPK pathway and suppresses the LPS signaling pathway. CCL22 is generally known to be chemotactic for monocytes, dendritic cells, natural killer cells and chronically activated T lymphocytes, suggesting that MSC-derived SCRG1 may block infiltration of these cells. A mechanism is proposed by which MSCs play their immunosuppressive role through suppressing chemokine expression in monocyte/macrophage lineage cells.
机译:最近,我们鉴定出间充质干细胞(MSCs)分泌的瘙痒病反应基因1(SCRG1)及其受体骨髓基质细胞抗原1(BST1)是干细胞质量(如自我更新,迁移能力和成骨细胞)的正向调节剂分化潜能。在这里,我们检查了巨噬细胞中SCRG1旁分泌活性的影响。小鼠巨噬细胞样细胞系Raw264.7表达BST1 /β1或BST1 /β2整合素可能是SCRG1受体。出乎意料的是,重组SCRG1不能增强这些巨噬细胞的细胞增殖,迁移或粘附。但是,对SCRG1在Raw264.7细胞中的作用的进一步检查确实显示出有效的抗炎作用,从而SCRG1抑制LPS诱导的CCL22产生。 SCRG1还诱导这些细胞中细胞外信号调节激酶1/2(ERK1 / 2)的磷酸化,此外,丝裂原激活的蛋白激酶(MAPK)/ ERK激酶抑制剂U0126显着抑制了SCRG1对LPS诱导的作用趋化因子CCL22的生产。总而言之,这些数据表明SCRG1通过MAPK途径发出信号,并抑制LPS信号途径。众所周知,CCL22对单核细胞,树突状细胞,自然杀伤细胞和长期激活的T淋巴细胞具有趋化作用,这表明MSC衍生的SCRG1可能会阻止这些细胞的浸润。提出了一种机制,通过该机制,MSC通过抑制单核细胞/巨噬细胞谱系细胞中的趋化因子表达来发挥其免疫抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号